Verona Pharma updates on RPL554 clinical trial

Verona Pharma's shares are up more than 1% after it confirmed the first patient had been dosed in its Phase 2a clinical trial evaluating RPL554 in the treatment of chronic obstructive pulmonary disease (COPD).

RPL554 was being used as an add-on therapy to tiotropium (Spiriva), a commonly used long-acting bronchodilator. Top-line data from the trial was expected in 4Q 2017.

At 10:43 GMT, shares in AIM-priced Verona were up 1.2% to 126.5p each.